Table 1.
Demographics of study population
| n (%) | |
|---|---|
| Patients enrolled and CM administered:1 |
515 |
| Male sex |
377 (73.2) |
| Age (mean±SD) |
60±10.3 years |
| Body mass index (mean±SD) |
28.2±4.3 kg/m2 |
| Risk factors: | |
| Hypertension |
358 (69.5) |
| Hypercholesterolemia |
354 (68.8) |
| Diabetes |
92 (17.8) |
| History of heart failure |
106 (20.6) |
| Myocardial infarction |
139 (27.0) |
| Percutaneous coronary intervention (PCI) |
170 (33.0) |
| Angina pectoris |
414 (80.4) |
| CCS I |
87 (16.9) |
| CCS II |
227 (44.1) |
| CCS III |
46 (8.9) |
| CCS IV |
21 (4.1) |
| Patients with all 3 test data sets complete (efficacy population): |
n 465 |
| Coronary artery disease |
227 (48.8) |
| Left main |
14 (3.0) |
| LAD |
134 (28.8) |
| LCX |
104 (22.4) |
| RCA |
112 (24.1) |
| Multivessel disease |
113 (24.3) |
| Myocardial infarction |
129 (27.7) |
| Medication: | |
| Any drugs |
496 (96.4) |
| Beta-blockers |
367 (71.3) |
| Lipid lowering |
354 (68.8) |
| Angiotensin-converting enzyme inhibitors |
306 (59.4) |
| Diuretics |
131 (25.5) |
| Calcium channel blockers |
99 (19.2) |
| Antithrombotic |
425 (82.6) |
| MR – not evaluable |
26 (5.6) |
| SPECT – not evaluable | 17 (3.7) |
CCS: Canadian Cardiovascular Society; LAD: left anterior descending coronary artery; LCX: left circumflex coronary artery; RCA: right coronary artery.
1 Eighteen patients were recruited but did not receive MR contrast medium, for reasons, see Flow chart in Figure 1.